Search

Your search keyword '"Rehwinkel H"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Rehwinkel H" Remove constraint Author: "Rehwinkel H"
41 results on '"Rehwinkel H"'

Search Results

1. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

6. Structure guided design and discovery of Indazole ethers as highly potent, non-steroidal Glucocorticoid receptor modulators

19. BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe.

20. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

21. Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.

22. Structural Evidence for Isoform-Selective Allosteric Inhibition of Lactate Dehydrogenase A.

23. Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases.

24. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

25. Discovery of new selective glucocorticoid receptor agonist leads.

26. Discovery of indazole ethers as novel, potent, non-steroidal glucocorticoid receptor modulators.

27. Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.

28. Identification of novel GLUT inhibitors.

29. Discovery of quinolines as selective glucocorticoid receptor agonists.

30. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.

31. GR ligands: can we improve the established drugs?

32. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index.

33. Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index.

34. Dissociated glucocorticoid receptor ligands.

35. Fluorinated dihydroquinolines as potent n-NOS inhibitors.

36. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.

37. Dihydroquinolines with amine-containing side chains as potent n-NOS inhibitors.

38. Dihydroquinolines as novel n-NOS inhibitors.

39. Novel prostanoid thromboxane A2 agonists.

40. Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor.

41. Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor.

Catalog

Books, media, physical & digital resources